CRISM Therapeutics Corporation (CRTX) fair value: what the stock is really worth
As of Sep 23, 2026: fair value of CRISM Therapeutics Corporation £0.01, price £0.10, upside -89.3%, quality 33 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch CRISM Therapeutics Corporation for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 24, 2026.
How to read this chart
60‑month range £0.0525 – £6.24 · fair‑value band £0.0104 – £0.0187 · the £0.0975 price screens above the £0.0104 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 24, 2026.
Follow CRISM Therapeutics in your weekly email
Every Wednesday you see whether CRISM Therapeutics is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
CRISM Therapeutics Corporation develops a drug delivery technology for the clinical performance of cancer treatments for solid tumors through the local delivery of chemotherapy drugs. Its lead product is ChemoSeed, an implantable biodegradable drug delivery technology for the delivery of chemotherapy directly into cancer tissues.
Show more
CRISM Therapeutics Corporation develops a drug delivery technology for the clinical performance of cancer treatments for solid tumors through the local delivery of chemotherapy drugs. Its lead product is ChemoSeed, an implantable biodegradable drug delivery technology for the delivery of chemotherapy directly into cancer tissues. The company also offers formulation and consultancy services. The company was formerly known as Amur Minerals Corporation and changed its name to CRISM Therapeutics Corporation in May 2024. CRISM Therapeutics Corporation was founded in 2016 and is based in Road Town, the British Virgin Islands.
Stock analysis
CRISM Therapeutics Corporation (CRTX) currently trades at £0.0975, while our model-based Fair Value estimate is £0.0104, implying the stock looks roughly 837.2% overvalued today.
Show more
Valuation
Bull case: the Asset-Based group reads highest at a median of £0.0100 per share, and 0 of the 3 models we run sit above the £0.0975 price.
Bear case: the Dividend Discount group reads lowest at £0.0100, and 3 of the 3 models stay below the price. Evidence for this calculation is low.
Scenario range: £0.0104 (bear) to £0.0187 (bull), the price of £0.0975 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 33/100 (below-average quality), in the Healthcare sector.
Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.
CRISM Therapeutics Corporation reported revenue of £231K in FY2025 versus £0 in FY2021. Reported net income was −£1.9M in FY2025.
Key figures
Market cap 7.5M GBX · EPS (TTM) £−0.0400 · Dividend yield 0.6% · Return on equity −88.1% · Return on assets (EBIT) −42.3% · Operating margin −5,952% · Free cash flow −2.0M GBX · Net cash 1.1M GBX.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 38 out of 100 (low confidence).
What moves the price
For context, the median of 10 Healthcare peers we cover trades at −5% fair-value upside, at −89%, CRTX screens richer than that median.
Fair Value models
Bear £0.0104Fair Value £0.0104Bull £0.0187
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.31/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
Compare CRISM Therapeutics Corporation with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 648 stocks
Beats the industry median on 1/7 measures
Overall it trails its industry peers.
Valuation
Quality Score33 · Bottom 25%
Fair Value upside−89% · Bottom 25%
Profitability
Return on assets−65% · Bottom 25%
Growth and dividend
Revenue growth0% · Above median
Dividend yield (TTM)0.6% · Below median
Valuation Multiplesvs Biotechnology median · lower = cheaper
P/B7.04× · Priciest 25%
P/S (TTM)43.13× · Priciest 25%
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 0
FUTURE (revenue growth)0· sector 0
PAST (return on equity)0· sector 0
HEALTH (low debt)0· sector 96
DIVIDEND (yield)12· sector 23
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is CRISM Therapeutics Corporation (CRTX) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of £0.0104 versus a price of £0.0975, about −89% upside (overvalued).
What is the fair value of CRTX?
Our model-based fair value for CRISM Therapeutics Corporation is £0.0104 (as of Sep 24, 2026), built from audited fundamentals. The current price: £0.0975.
What is the quality score of CRTX?
CRISM Therapeutics Corporation has a Quality Score of 33/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for CRISM Therapeutics Corporation (CRTX)?
Our model-based price target is the fair value of £0.0104 (as of Sep 24, 2026) from 3 valuation models. Cautious scenario £0.0104, optimistic scenario £0.0187. It is a calculation from audited fundamentals, not an analyst target.
What is the CRISM Therapeutics Corporation stock forecast for 2026?
Our models put fair value at £0.0104, about −89% upside versus a price of £0.0975 (overvalued). Cautious scenario £0.0104, optimistic scenario £0.0187. The calculation is refreshed regularly with new filings.
Does CRISM Therapeutics Corporation pay a dividend?
CRISM Therapeutics Corporation currently shows a dividend yield of about 0.62% relative to its recent price (as of Sep 24, 2026).
What is the intrinsic value of CRISM Therapeutics Corporation (CRTX)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For CRISM Therapeutics Corporation it is £0.0104 per share (as of Sep 24, 2026), against a price of £0.0975. It is the blended result of 3 valuation models (cash flow, earnings, asset, dividend).
Is CRISM Therapeutics Corporation stock overvalued or undervalued in 2026?
As of Sep 24, 2026, CRTX trades above its calculated fair value: price £0.0975, fair value £0.0104, a gap of about −89% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of CRTX?
No. The price is what the market pays today (£0.0975); the fair value is what the company's own numbers justify (£0.0104). For CRISM Therapeutics Corporation the two are £0.0871 per share apart. That gap is exactly why we show both numbers side by side.
How much is CRISM Therapeutics Corporation worth?
The market values CRISM Therapeutics Corporation at about 7.5M GBX (market capitalisation, as of Sep 24, 2026). Per share that is £0.0975; our models calculate a fair value of £0.0104 per share.
What do the bullish and bearish scenarios say about CRTX?
Our models span a range for CRISM Therapeutics Corporation: cautious scenario £0.0104, base £0.0104, optimistic £0.0187 per share (as of Sep 24, 2026, price £0.0975). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of CRISM Therapeutics Corporation (CRTX)?
Balance-sheet figures for CRISM Therapeutics Corporation (as of Sep 24, 2026): return on equity −129.8%. They feed the Quality Score of 33/100, which measures business quality independently of the share price.
Which stocks are comparable to CRISM Therapeutics Corporation?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, argenx SE, Samsung Biologics Co, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is CRISM Therapeutics Corporation stock attractive at the current price?
The data as of Sep 24, 2026: price £0.0975, calculated fair value £0.0104 (−89%), Quality Score 33/100, from 3 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of CRTX calculated?
We run CRISM Therapeutics Corporation through 3 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of £0.0104, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.1 % above its aggregate fair value. CRISM Therapeutics Corporation itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of CRISM Therapeutics Corporation (CRTX)?
The closing price on Sep 23, 2026 was £0.0975. Our model-based fair value is £0.0104, about −89% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with CRISM Therapeutics Corporation right now?
The price sits above even our optimistic bull case (£0.0187). The favourable scenario is already priced in. Weak quality (33/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.
Key figures of CRISM Therapeutics Corporation
How large is the market capitalisation of CRISM Therapeutics Corporation (CRTX)?
The market capitalisation of CRISM Therapeutics Corporation is 7.5M GBX. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What are the earnings per share of CRISM Therapeutics Corporation (CRTX)?
Earnings per share at CRISM Therapeutics Corporation are £−0.0400. Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of CRISM Therapeutics Corporation (CRTX)?
The dividend yield of CRISM Therapeutics Corporation is 0.6%. Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the return on equity of CRISM Therapeutics Corporation (CRTX)?
The return on equity (ROE) of CRISM Therapeutics Corporation is −88.1% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of CRISM Therapeutics Corporation (CRTX)?
On an EBIT basis the return on assets of CRISM Therapeutics Corporation is −42.3% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of CRISM Therapeutics Corporation (CRTX)?
The operating margin of CRISM Therapeutics Corporation is −5,952% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How much free cash flow does CRISM Therapeutics Corporation (CRTX) generate?
The free cash flow of CRISM Therapeutics Corporation is −2.0M GBX (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does CRISM Therapeutics Corporation (CRTX) hold?
CRISM Therapeutics Corporation holds more cash than debt, 1.1M GBX net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed
Watch CRISM Therapeutics Corporation in the live analysis
One click puts CRISM Therapeutics Corporation on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
